NASDAQ:CABA Cabaletta Bio Q1 2025 Earnings Results & Report $1.45 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.03 (+2.14%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cabaletta Bio missed analyst earnings expectations in its Q1 2025 results, released May 21, 2025. The company reported EPS of -$0.71 versus the -$0.67 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 21, 2025TimeBefore Market OpensConference Call DateMay 15, 2025Conference Call9:30 AM ET Cabaletta Bio EPS ResultsActual EPS-$0.71Consensus EPS -$0.67Beat/MissMissed by -$0.04One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCabaletta Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Cabaletta Bio Q1 2025 Earnings FAQ Did Cabaletta Bio beat earnings estimates for Q1 2025? Cabaletta Bio (NASDAQ:CABA) reported earnings of -$0.71 per share for Q1 2025, missing the consensus estimate of -$0.67. The report was announced on Wednesday, May 21, 2025. Cabaletta Bio Earnings HeadlinesCabaletta Bio (NASDAQ:CABA) Stock Price Target Cut by CitigroupNovember 11 at 2:07 AM | americanbankingnews.comCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data At ACR Convergence 2026November 10 at 8:52 AM | marketscreener.comMToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Cabaletta Bio Reports Positive Phase 1/2 Data For Rese-cel In Autoimmune Diseases; Stock UpNovember 9 at 7:48 AM | rttnews.comFY2030 EPS Estimate for Cabaletta Bio Decreased by AnalystNovember 9 at 1:59 AM | americanbankingnews.comCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across ...November 8 at 2:47 PM | markets.businessinsider.comSee More Cabaletta Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cabaletta Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cabaletta Bio and other key companies, straight to your email. Email Address About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a clinical-stage biotechnology company developing engineered T-cell therapies for people with autoimmune diseases. The company’s approach aims to address disease-causing immune cells while limiting disruption to the broader immune system. Its lead program, CABA-201, is an investigational CD19-directed CAR T-cell therapy being studied across several autoimmune conditions. Cabaletta is also developing DSG3-CAART, an engineered cell therapy designed to target B cells that produce antibodies associated with pemphigus vulgaris. Founded in 2017 and based in Philadelphia, Cabaletta has no approved products; its programs remain in clinical development.View Cabaletta Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
